Us2.ai receives FDA clearance for Us2.v2,transforming…

Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced interim results of a six month non-human primate toxicology study with clinical candidate CEQ508. CEQ508 was administered in an oral suspension once daily to non-human primates for over 180 consecutive days at a dose level of 10(11) colony forming units (cfu)/day. During this period of time, no toxicity or test article related adverse events were observed. To support the potential requirements of a Phase 2 clinical trial, the non-human primate study was extended for an additional three months. CEQ508 is Marina Biotech's clinical candidate for the treatment of Familial Adenomatous Polyposis (FAP), and is expected to begin dosing in patients in a Phase 1b/2a trial this quarter.